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Abstract
There is scant information on the prevalence and factors associated
with preoperative anemia in patients undergoing transcatheter aortic valve
implantation (TAVI) and whether it is associated with mortality. We sought to
determine the prevalence and factors associated with preoperative anemia in
addition to the prognostic effects of the various levels of preoperative hemoglobin
level on mortality in patients undergoing TAVI.
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Background—There is scant information on the prevalence and factors associated with preoperative anemia in patients 
undergoing transcatheter aortic valve implantation (TAVI) and whether it is associated with mortality. We sought to 
determine the prevalence and factors associated with preoperative anemia in addition to the prognostic effects of the 
various levels of preoperative hemoglobin level on mortality in patients undergoing TAVI.
Methods and Results—Ten-center observational study encompassing 1696 patients with aortic stenosis who underwent 
TAVI was conducted. Anemia was defined by the World Health Organization criteria (hemoglobin <12.0 g/dL in 
women and <13.0 g/dL in men). The prevalence of preoperative anemia was 57%. Patient-related factors associated 
with preoperative anemia were (descending order of odds ratio [95% confidence interval]) as follows: anemia-
related medication (4.90 [3.08–7.80]), history of heart failure (1.77 [1.43–2.20]), male sex (1.69 [1.32–2.16]), mitral 
regurgitation grade ≥III (1.61 [1.15–2.25]), history of malignancy (1.44 [1.03–2.09]), and peripheral vascular disease 
(1.33 [1.04–1.70]). The creatinine clearance was inversely associated with preoperative anemia (odds ratio, 0.92 [0.87–0.97]). 
In multivariable analyses, preoperative anemia was not associated with 30-day mortality (1.72 [0.96–3.12]; P=0.073) 
but showed the strongest association with 1-year mortality with a hazard ratio (95% confidence interval) of 2.78 (1.60–4.82) 
in patients with hemoglobin <10 g/dL. Patients with anemia received ≥1 blood transfusion 2× more often, but the 
indication of transfusion was unrelated to overt bleeding in 60%. Blood transfusion was associated with mortality at 30 
days (odds ratio, 1.25 [95% confidence interval, 1.08–3.67]) and during follow-up (hazard ratio, 1.09 [95% confidence 
interval, 1.03–1.14]).
Conclusions—Preoperative anemia is prevalent in >50% of patients undergoing TAVI. Various baseline factors were related 
to anemia, which in turn was associated with 1-year mortality. Patients with anemia received more transfusions but mostly 
for indications unrelated to overt bleeding, whereas transfusion was independently associated with both early and 1-year 
mortality. These findings indicate that optimization of baseline factors related to preoperative anemia, in addition to more 
strict criteria of the use of blood products, may improve outcome after TAVI.  (Circ Cardiovasc Interv. 2013;6:625-634.)
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Transcatheter aortic valve implantation (TAVI) is increas-ingly used to treat patients with aortic stenosis who are 
considered at high risk for surgical aortic valve replace-
ment.1,2 These patients, therefore, often have preexisting 
comorbid conditions that may affect outcome, offsetting 
treatment effects.
Anemia is a common finding in (elderly) patients and has 
been shown to be an independent risk factor for early and late 
mortality in the general and elderly population,3,4 in patients 
with coronary artery disease including acute coronary syn-
drome5 and heart failure,6,7 and in patients undergoing percu-
taneous and surgical cardiac interventions.8–13
In a recent study including 118 patients who underwent 
TAVI, preoperative anemia was seen in half of the patients and 
was associated with increased 1-year mortality.14 Yet, the rela-
tionship between the degree of preoperative anemia and the 
effect of confounders because of differences in baseline risk 
between patients with and without anemia on outcome need 
further elucidation. In addition, no data are available describ-
ing the causes of anemia in this population. Such informa-
tion may be helpful because the measures aimed at correcting 
or treating anemia, and its cause may conceptually improve 
operative outcome.15
We, therefore, sought to determine the prevalence and asso-
ciated factors of preoperative anemia in addition to the effects 
of the various levels of preoperative hemoglobin (Hb) concen-




The study population stems from a cohort of 1706 patients who un-
derwent TAVI with the Medtronic CoreValve System (Medtronic 
Inc, Minneapolis, MN), the Edwards SAPIEN or SAPIEN XT Valve 
(Edwards Lifesciences, Irvine, CA), or the Direct Flow Valve (Direct 
Flow Medical, Inc, Santa Rosa, CA) from November 2005 to March 
2013 in the following institutions: (1) Rotterdam Thoraxcenter, 
the Netherlands (n=322); (2) Quebec Heart and Lung Institute, 
Canada (n=287); (3) University Hospital Bonn, Germany (n=255); 
(4) Bergmannsheil, Ruhr-University Bochum, Germany (n=202); 
(5) University Hospital Maastricht, the Netherlands (n=145); (6) 
University Hospital Saint-Luc, Belgium (n=122); (7) University 
Hospital Antwerp, Belgium (n=120); (8) Angiografia de Occidente, 
Colombia (n=93); (9) Royal Perth Hospital, Australia (n=90); and 
(10) Hospital Clínico Universitario de Valladolid, Spain (n=70). 
Patients with missing baseline Hb values (n=10) were excluded, re-
sulting in a final study population consisting of 1696 patients.
In accordance with the institutions’ policies, every patient gave 
written informed consent for TAVI and the use of anonymous clini-
cal, procedural, and follow-up data for research in accordance with 
institutional review board approval.
Procedure
Planning and execution of TAVI have been described previously.16 
All procedures were performed under local or general anesthesia us-
ing the Medtronic CoreValve System (valve sizes 23, 26, 29, and 31 
mm), the Edwards SAPIEN or SAPIEN XT Valve (valve sizes 23, 26, 
and 29 mm), or the Direct Flow Valve (valve sizes 24 and 25 mm). 
After TAVI, antiplatelet therapy consisted of clopidogrel 75 mg for 6 
months and aspirin 80 to 100 mg indefinitely. Patients on oral antico-
agulant therapy before TAVI received periprocedural therapeutic an-
ticoagulation with unfractionated heparin or low–molecular-weight 
heparin in combination with either clopidogrel or aspirin. Oral anti-
coagulation was resumed shortly after TAVI.
Definitions and Data Collection
In each hospital, blood samples for hematology and chemistry 
were taken before and at fixed intervals ≤72 hours after TAVI and 
included the nadir Hb concentration, maximum serum creatinine, 
and maximum leukocyte count. Preoperative anemia was defined 
according to the American College of Physicians and World Health 
Organization criteria as a preoperative Hb level <12.0 g/dL in wom-
en and <13.0 g/dL in men.17 Patients were also divided into catego-
ries of 1.0-g/dL Hb increments from <10.0 to ≥15 g/dL to assess the 
dose-dependent effects of decreased versus normal preoperative Hb 
level on mortality.
Preoperative serum creatinine values were used to calculate 
the baseline serum creatinine clearance using the Cockcroft and 
Gault equation.18 In accordance with the Kidney Disease Outcomes 
Quality Initiative guidelines, preoperative kidney function was 
classified as stage I (>90 mL/min per 1.73 m2), stage II (60–89 mL/
min per 1.73 m2), stage III (30–59 mL/min per 1.73 m2), stage IV 
(15–29 mL/min per 1.73 m2), and stage V (<15 mL/min per 1.73 
m2), with stage ≥II indicating chronic kidney disease.19
After TAVI, the nadir Hb concentration was determined ≤24 and 
≤72 hours after TAVI and was used to define the Hb decline relative 
to the patient’s preoperative Hb value. The number of units of blood 
transfusions was determined at 4 time intervals: before and at ≤24 
hours, >24 to ≤72 hours, and >72 hours after TAVI. Details of the in-
dications of blood transfusions, in addition to the time of onset of the 
indications, were documented and used to determine whether there 
was an overt bleeding source that was defined by a clinically visible 
bleeding source or imaging-documented bleeding (ie, angiography, 
computed tomography, echo of blood vessels, or other organs). All 
end points were defined according to the Valve Academic Research 
Consortium recommendations.20
Follow-up
Follow-up data on patient mortality were collected from the civil 
registries or the referring physician or general practitioner and was 
complete for all the patients at 30 days after TAVI and for 99.3% 
at follow-up (median, 356 [interquartile range, 90–680] days). Of 
all 449 patients who died during follow-up, the cause of death was 
confirmed in 88.4%, unknown in 7.3%, and missing/not assessed in 
4.2%. The cause of death grouped according to the presence of pre-
operative anemia is listed in the online-only Data Supplement and 
WhAT IS KNOWN
•	Preoperative anemia is a common finding in elderly 
patients, in patients with heart disease, and in pa-
tients undergoing percutaneous and surgical cardiac 
interventions.
WhAT ThE STUDY ADDS
•	Preoperative anemia is prevalent in more than half 
of patients undergoing transcatheter aortic valve 
implantation.
•	Various baseline factors are associated with anemia, 
which in turn is strongly associated with 1-year mor-
tality but not with early mortality.
•	Patients with anemia receive more transfusions 
mostly for indications unrelated to overt bleeding, 
whereas transfusion is independently associated with 
both early and 1-year mortality.
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classified as cardiovascular or noncardiovascular in accordance with 
the Valve Academic Research Consortium criteria.20
Statistical Analysis
Details of data completeness and management are summarized in 
the online-only Data Supplement. Categorical variables are summa-
rized as frequencies and percentages and were compared using the χ2 
test or Fisher exact test. The Shapiro–Wilk test was used to test for a 
normal distribution of continuous variables, and comparison of con-
tinuous variables was performed using the Student t tests or Wilcoxon 
rank-sum test when appropriate. The factors associated with preop-
erative anemia were assessed using forward stepwise logistic regres-
sion analyses, including all variables from Table 1 with P<0.10 in the 
univariable analysis. Associations with 30-day and cumulative 1-year 
mortality after TAVI were assessed by, respectively, forward stepwise 
logistic and Cox regression analyses, including all variables from 
Table 1. Baseline Characteristics of Patients Undergoing Transcatheter Aortic Valve Implantation 







Age, y, mean±SD 81±7 80±7 81±7 0.001
Male, n (%) 884 (52) 343 (47) 541 (56) <0.001
  Height, mean±SD, cm 165±9 166±9 165±10 0.055
  Weight, mean±SD, kg 72±15 74±15 71±14 0.002
  Body mass index, mean±SD, kg/m2 26.5±4.8 26.8±5.0 26.3±4.7 0.049
  Body surface area, mean±SD, m2 1.81±1.80 1.83±0.22 1.80±0.20 0.002
New York Heart Association class ≥III, n (%) 1416 (84) 584 (80) 832 (86) 0.002
  Previous cerebrovascular event 311 (18) 121 (17) 190 (20) 0.12
  Previous myocardial infarction 438 (26) 174 (24) 264 (27) 0.12
  Previous coronary artery bypass graft surgery 411 (24) 184 (25) 227 (24) 0.38
  Previous percutaneous coronary intervention 533 (32) 210 (29) 323 (33) 0.054
History of heart failure, n (%) 962 (57) 337 (47) 625 (65) <0.001
Diabetes mellitus, n (%) 477 (28) 187 (26) 290 (30) 0.057
Hypertension, n (%) 1300 (77) 553 (76) 747 (77) 0.62
Peripheral vascular disease, n (%) 473 (28) 168 (23) 305 (32) <0.001
Chronic obstructive pulmonary disease, n (%) 473 (28) 196 (27) 277 (29) 0.46
Atrial fibrillation, n (%) 476 (28) 186 (26) 290 (30) 0.049
Permanent pacemaker, n (%) 216 (13) 82 (11) 134 (14) 0.12
History of malignancy, n (%)
  All 197 (12) 72 (10) 125 (13) 0.057
  Gastrointestinal or hematologic 63 (4) 20 (3) 43 (4) 0.069
Anemia-related medication
  All 164 (10) 24 (3) 140 (14) <0.001
  Iron supplements 120 (7) 17 (2) 103 (11)
  Erythropoietin 20 (1.2) 5 (1) 15 (2)
  Blood transfusions 12 (0.7) 1 (0.1) 11 (1)
  Combination therapy* 8 (0.4) 1 (0.1) 7 (1)
Laboratory results
  Creatinine, median (IQR), μmol/L 99 (80–128) 93 (78–116) 105 (84–138) <0.001
  Creatinine clearance, mean±SD, mL/min 50±22 54±22 47±22 <0.001
  Hemoglobin, mean±SD, g/dL 12.1±1.7 13.6±1.0 11.0±1.1 <0.001
  Leukocyte count (×109/L), mean±SD 7.3±2.2 7.4±2.0 7.2±2.3 0.039
Echocardiography
  Left ventricular ejection fraction, mean±SD 52±14 53±14 52±15 0.11
  Aortic valve area, mean±SD, cm2 0.68±0.20 0.68±0.19 0.68±0.20 0.74
  Peak gradient, mean±SD 72±25 72±23 72±26 0.70
  Mitral regurgitation grade ≥ III, n (%) 216 (13) 66 (9) 150 (16) <0.001
  Aortic regurgitation grade ≥ III, n (%) 137 (8) 51 (7) 86 (9) 0.16
Logistic EuroSCORE, median (IQR) 19.0 (11.0–30.7) 17.0 (10.1–26.0) 20.8 (12.4–33.5) <0.001
EuroSCORE indicates European System for Cardiac Operative Risk Evaluation; and IQR, interquartile range.
*Ferrofumarate/erythropoietin treatment (n=4) and ferrofumarate/blood transfusion treatment (n=4).
628  Circ Cardiovasc Interv  December 2013
Tables 1 and 2 with P<0.10 in the univariable analyses.21 An excep-
tion was made for aortic regurgitation after TAVI, which was forced 
into the multivariable model independent of the P value (which 
proved to be 0.12), given its established predictive effect on 1-year 
mortality.22–27 The relationship between low preoperative Hb level and 
outcome was assessed by forcing this variable into the model of 30-
day and 1-year mortality both as a continuous and a dichotomous 
variable (anemia). This was also done for Hb coded as a multicat-
egory predictor in 1-g/dL increments, with the Hb category exhibiting 
the lowest event rate used as the reference group.5 Interaction terms 
were tested to evaluate the potential additive and synergistic harmful 
effects of baseline anemia and Hb decline at ≤24 and ≤72 hours after 
TAVI. Variables included in the multivariable model of determinants 
of preoperative anemia, 30-day mortality, and 1-year mortality are 
listed in the online-only Data Supplement. Results are reported as 
adjusted odds ratio (OR) or hazard ratio (HR) with a 95% confidence 
interval (CI). Kaplan–Meier methods were used to illustrate the tim-
ing of events during follow-up; statistical assessment was performed 
Table 2. Perioperative Results of Patients Undergoing 
Transcatheter Aortic Valve Implantation Grouped According to 
the Presence of Preoperative Anemia




Intraoperative or ≤24 h
  Early experience, n (%)* 134 (18) 192 (20) 0.48
  Device, n (%)
   Medtronic CoreValve 444 (61) 572 (59) 0.41
   Edwards Sapien 275 (38) 391 (41) 0.28
   Direct Flow Medical 6 (0.8) 2 (0.2) 0.081
  Access strategy, n (%)
   Transfemoral 565 (78) 719 (74) 0.16
   Transapical 140 (19) 202 (21)
   Trans-subclavian 13 (2) 31 (3)
   Transaortic 8 (1) 16 (2)
  Circulatory support, n (%) 21 (3) 27 (3) 0.90
  Prosthesis size, n (%)†
   20, 23, 25 mm 152 (21) 198 (21) 0.82
   26, 29, 31 mm 573 (79) 767 (80)
  Postimplantation balloon  
dilation, n (%)
104 (14) 177 (18) 0.030
  Duration of procedure, min, 
mean±SD
121±74 112±65 0.022
  Hemoglobin, g/dL, mean±SD
   Preprocedural 13.6±1.0 11.0±1.1 <0.001
   Postprocedural 10.9±1.7 9.5±1.3 <0.001
   Decline 2.7±1.5 1.5±1.4 <0.001
  Blood transfusion, n (%)
   None 624 (86) 686 (71) <0.001
   1–2 U 69 (10) 223 (23)
   3–4 U 14 (2) 42 (4)
   ≥5 U 20 (3) 18 (2)
Postoperative ≤72 h
  Serum creatinine, median  
(IQR), μmol/L
   Preprocedural 93 (78–116) 105 (84–138) <0.001
   Postprocedural 90 (73–119) 100 (75–139) <0.001
  Creatinine clearance, 
mean±SD, mL/min
   Preprocedural 54±22 47±22 <0.001
   Postprocedural 58±38 53±39 0.017
  Leukocyte count (×109/L),  
mean±SD
   Preprocedural 7.4±2.0 7.2±2.3 0.039
   Postprocedural 11.8±4.2 11.7±6.0 0.65
  Hemoglobin, mean±SD, g/dL
   Postprocedural 10.31±1.7 9.0±1.3 <0.001
   Decline 3.3±1.5 2.0±1.3 <0.001
  Blood transfusion, n (%)
   None 569 (78) 519 (54) <0.001
   1–2 U 102 (14) 307 (32)
   3–4 U 27 (4) 98 (10)




   Peak gradient, mean±SD 18±9 18±10 0.24
   Mitral regurgitation  
grade ≥III, n (%)
45 (7) 102 (12) 0.001
   Aortic regurgitation  
grade ≥III, n (%)
37 (5) 52 (6) 0.72
Length of stay, median (IQR), d 8 (6–14) 10 (7–16) <0.001
In-hospital complications
  Mortality (≤30 d)‡
   All-cause 36 (5) 92 (10) <0.001
   Cardiovascular 25 (3) 63 (7) 0.005
   Noncardiovascular 11 (2) 28 (3) 0.061
  Myocardial infarction  
(periprocedural, ≤72 h)
15 (2) 12 (1) 0.18
  Cerebrovascular complications
   Major stroke 14 (2) 28 (3) 0.21
   Minor stroke 12 (2) 5 (1) 0.020
   TIA 8 (1) 5 (0.5) 0.17
  Vascular complication, n (%)
   Major 59 (8) 92 (10) 0.32
   Minor 70 (10) 84 (9) 0.50
  Bleeding complication, n (%)
   Life-threatening or disabling 32 (4) 41 (4) 0.86
   Major 47 (7) 83 (9) 0.11
   Minor 54 (7) 86 (9) 0.28
  Acute kidney injury, n (%)
   Stage 1 87 (12) 120 (12) 0.80
   Stage 2 10 (1) 20 (2) 0.29
   Stage 3 24 (3) 42 (4) 0.28
  Combined 30-day safety  
end point
125 (17) 222 (23) 0.004
IQR indicates interquartile range; and TIA, transient ischemic attack.
*Early experience represents the first 33 patients in each center who 
underwent transcatheter aortic valve implantation.21
†Six patients did not receive a valve because of death before valve insertion.
‡The cause of death was missing in 1 patient who died ≤30 days.
Table 2. Continued
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by the log-rank test. Patients lost to follow-up (0.7%) were consid-
ered at risk until the date of last contact at which point they were 
censored. A 2-sided P<0.05 was considered to indicate significance, 
and all statistical analyses were performed with SPSS software ver-
sion 20.0 (IBM, Chicago, IL).
Results
The overall prevalence of preoperative anemia was 57% and 
varied between 42% and 67% in the participating hospitals. 
The mean preoperative Hb concentration was 12.1±1.7 g/dL 
(range, 7.2–17.5 g/dL). The distribution of preoperative Hb 
concentration is presented in Figure 1.
Factors Associated With Anemia
Baseline patient characteristics and operative details of the 
1696 patients are summarized in Tables 1 and 2. Patients with 
anemia were older (81 versus 80 years; P<0.001), more fre-
quently men (56% versus 47%; P<0.001), and had a lower 
body mass index (26.3 versus 26.8 kg/m2; P=0.049) and body 
surface area (1.80 versus 1.83 m2; P=0.002). They were also 
more symptomatic (New York Heart Association class ≥III, 
86% versus 81%; P=0.002), more often had a history of 
heart failure (65% versus 47%; P<0.001) and chronic treat-
ment for anemia (14% versus 3%; P<0.001), and had a higher 
prevalence of peripheral vascular disease (32% versus 23%; 
P<0.001), atrial fibrillation (30% versus 26%; P=0.049), and 
mitral regurgitation grade ≥III (16% versus 9%; P<0.001) but 
showed a lower preoperative creatinine clearance (47 ver-
sus 54 mL/min; P<0.001) and leukocyte count (7.2 versus 
7.4×109 cells/L; P=0.037). They, therefore, had a higher esti-
mated operative risk (logistic European System for Cardiac 
Operative Risk Evaluation [EuroSCORE]: 21% versus 17%; 
P<0.001) compared with patients without anemia. The base-
line patient characteristics associated with preoperative ane-
mia by multivariable analysis are shown in Table 3. As shown 
Figure 1. Distribution of preoperative hemoglobin 
concentration in patients undergoing transcatheter 
aortic valve implantation.
Table 3. Multivariable Logistic Regression Analysis for Factors Associated With Preoperative 
Anemia in Patients Undergoing Transcatheter Aortic Valve Implantation
Entire Cohort (n=1696)
No Chronic Use of Anemia-Related 
Medication (n=1532)
Odds Ratio (95% CI) P Value Odds Ratio (95% CI) P Value
Categorical variables
  Anemia-related medication 4.90 (3.08–7.80) <0.001 NA NA
  History of heart failure 1.77 (1.43–2.20) <0.001 1.85 (1.48–2.30) <0.001
  Male sex 1.69 (1.32–2.16) <0.001 1.69 (1.31–2.18) <0.001
  Preoperative mitral regurgitation grade ≥III 1.61 (1.15–2.25) 0.005 1.61 (1.14–2.28) 0.007
  History of malignancy 1.44 (1.03–2.09) 0.033 1.63 (1.15–2.32) 0.006
  Peripheral vascular disease 1.33 (1.04–1.70) 0.023 1.32 (1.03–1.70) 0.030
Continuous variables
  Preoperative creatinine clearance (per 
10 mL/min increase)
0.92 (0.87–0.97) 0.001 0.91 (0.86–0.96) <0.001
  Preoperative leukocyte count (per 1×109 
cells/L increase)
0.95 (0.91–0.99) 0.034 0.95 (0.90–0.99) <0.001
  Logistic EuroSCORE (per 1% increase) 1.01 (1.00–1.02) 0.017 1.01 (1.00–1.02) 0.012
CI indicates confidence interval; and EuroSCORE, European System for Cardiac Operative Risk Evaluation.
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in Figure 2, the severity of kidney dysfunction was inversely 
proportional to the Hb concentration in the overall cohort, 
except in patients who were on chronic treatment for anemia.
Preoperative Anemia and Transfusions
A total of 694 patients (41%) underwent ≥1 blood transfu-
sion during or after TAVI. Figure 3A shows that patients with 
anemia consistently had ≥1 U of blood transfusions 2× more 
frequently before and at each time interval after TAVI com-
pared with patients without anemia (P<0.001). As shown in 
Figure 3B, the indication of blood transfusion was more often 
not related to an overt bleeding source in patients with ane-
mia (60% versus 46%; P<0.001). Details of the indications 
of transfusion therapy are listed in Table 4; the most frequent 
indication was operative blood loss in patients with anemia 
and access site complication in nonanemic patients.
Thirty-Day Mortality
Thirty-day all-cause mortality was 5% in patients without and 
10% in patients with anemia (P<0.001). Associations with 
Figure 2. Preoperative hemoglobin 
concentration per category of kidney 
dysfunction in patients undergoing 
transcatheter aortic valve implantation 
in the entire cohort and in patients with 
and without drugs for the treatment of 
anemia. Preoperative kidney function 
was classified according to the Kidney 
Disease Outcomes Quality Initiative 
guidelines as stage I (>90 mL/min per 
1.73 m2), stage II (60–89 mL/min per 1.73 
m2), stage III (30–59 mL/min per 1.73 m2), 
stage IV (15–29 mL/min per 1.73 m2), and 
stage V (<15 mL/min per 1.73 m2).
Figure 3. A, Timing and num-
ber of blood transfusions in 
patients undergoing transcath-
eter aortic valve implantation 
grouped according to the pres-
ence of preoperative anemia. 
B, Timing of the indication of 
blood transfusion therapy in 
patients undergoing transcath-
eter aortic valve implantation 
grouped according to the pres-
ence of preoperative anemia. 
Analysis includes 1 (ie, the first) 
indication of blood transfusion 
per patient (a second indication 
was found in 33 [5%] and 103 
[11%] patients without and with 
anemia, respectively [P<0.001]). 
*Overt bleeding is defined by a 
clinically visible bleeding source 
or imaging-documented bleed-
ing (ie, angiography, computed 
tomography, echo of blood 
vessels, or other organs).
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30-day all-cause mortality are shown in Table 5. With respect 
to the dichotomous variables, postoperative aortic regurgitation 
grade ≥III (OR, 5.07; 95% CI, 2.02–12.65) showed the strongest 
association with 30-day mortality followed by—in descend-
ing order of odds—acute kidney injury (OR, 3.21; 95% CI, 
1.83–5.64), male sex (OR, 2.25; 95% CI, 1.25–4.06), postop-
erative mitral regurgitation (OR, 2.13; 95% CI, 1.06–4.27), and 
preoperative atrial fibrillation (OR, 2.03; 95% CI, 1.16–3.53), 
whereas preoperative anemia was not related to mortality (OR, 
1.72; 95% CI, 0.96–3.12). With respect to continuous variables, 
the administration of every unit of blood transfusion was associ-
ated with a 25% higher risk of 30-day mortality, whereas every 
1% increase in logistic EuroSCORE increased the risk of death 
by 3%. The peak aortic valve gradient before TAVI proved to 
have an inverse relationship with mortality.
One-Year Mortality
At 1 year, all-cause mortality was 21% in patients without and 
31% in patients with anemia (P<0.001); patients with anemia 
more frequently died because of pneumonia (P=0.024). Asso-
ciations with all-cause mortality during follow-up by mul-
tivariable analysis are shown in Table 6. With respect to the 
dichotomous variables, a significant and inverse relationship 
was found between the severity of preoperative Hb level and 
mortality during follow-up. In particular, patients with a pre-
operative Hb level <10 g/dL had a 2.8-fold higher risk of dying 
during the follow-up period, whereas patients with a preopera-
tive Hb level between 10 to 11 and 11 to 12 g/dL had a 2.5- 
and 1.9-fold high risk, respectively. Postoperative acute kidney 
injury (HR, 1.97; 95% CI, 1.53–2.54) and preoperative atrial 
fibrillation (HR, 1.77; 95% CI, 1.41–2.23), in addition to aortic 
regurgitation grade ≥III (HR, 1.66; 95% CI, 1.09–2.53), male 
sex (HR, 1.53; 95% CI, 1.22–1.93), history of malignancy (HR, 
1.51; 95% CI, 1.12–2.04), and history of peripheral vascular 
disease (HR, 1.34; 95% CI, 1.05–1.70), were also associated 
with 1-year mortality. Similar to 30-day mortality, the admin-
istration of blood transfusion was related to mortality during 
follow-up; every unit of transfusion was associated with a 9% 
increase in risk of late death. This also accounted for leukocyte 
count after TAVI and logistic EuroSCORE (ie, 5% increase in 
risk of late death for every 1% increase in logistic EuroSCORE), 
whereas left ventricular ejection fraction, body mass index, and 
peak gradient proved to have an inverse relationship with 1-year 
mortality. Kaplan–Meier estimates of survival of patients with-
out and with preoperative anemia are shown in Figure 4.
Discussion
In this multicenter study encompassing 1696 patients who 
underwent TAVI, we found that preoperative anemia was 
present in 57% of patients with an equal distribution of its 
prevalence in the participating institutions (range, 42%–67%). 
Factors related to the presence of anemia included history 
of heart failure, male sex, preoperative mitral regurgitation, 
history of malignancy, peripheral vascular disease, and kid-
ney dysfunction. Despite differences in baseline characteris-
tics between patients with and without preoperative anemia, 
multivariable analyses showed that preoperative anemia was 
associated with 1-year mortality (10% and 31%, respectively). 
Table 4. Blood Transfusion Indications During and After Transcatheter Aortic Valve 








Related to overt bleeding 240 (14) 86 (12) 154 (16) <0.001
  Access site complication 151 (10) 52 (7) 99 (10) 0.028
   Transfemoral 128 (8) 45 (6) 83 (9) 0.067
   Transapical 14 (1) 4 (0.6) 10 (1) 0.28
  Cardiac tamponade 24 (1) 12 (2) 12 (1) 0.48
  Late-onset hematoma near access site 14 (1) 5 (0.7) 9 (1) 0.59
  Retroperitoneal hemorrhage 11 (0.6) 6 (1) 5 (0.5) 0.43
  Gastrointestinal bleeding 7 (0.4) 2 (0.3) 5 (0.5) 0.71
  Hematuria 5 (0.3) 1 (0.1) 4 (0.4) 0.40
  Hematothorax 5 (0.3) 2 (0.3) 3 (0.3) 1.0
  Cardioversion to surgical valve replacement 4 (0.2) 2 (0.3) 2 (0.2) 0.77
  Jugular vein bleeding 4 (0.2) 0 4 (0.4) 0.14
  Other* 15 (1) 4 (0.6) 12 (1.2) 0.15
Not related to overt bleeding 387 (23) 85 (12) 302 (31) <0.001
  Operative blood loss 223 (13) 42 (6) 181 (19) <0.001
  Hemoglobin decline without bleeding source 164 (10) 43 (6) 121 (13) <0.001
Unknown 67 (4) 15 (2) 52 (5) 0.001
Analysis includes only 1 indication of blood transfusion per patient (a second indication was found in 33 [5%] and 103 
[11%] patients without and with anemia, respectively [P<0.001]).
*Hemolysis (n=2), intubation complicated with pharynx bleeding (n=2), bleeding after thrombolysis (n=2), pocket 
hematoma after pacemaker implantation (n=2), dialysis-related blood loss (n=1), preoperative gastrointestinal bleeding 
(n=1), surgical intervention peripheral vessels (n=1), intracranial bleeding (n=1), sepsis (n=1), annular rupture (n=1), and 
liver laceration after chest compression (n=1).
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Furthermore, a significant inverse relationship was found 
between the severity of preoperative anemia (ie, serum Hb 
level) and mortality during follow-up. This was, in particular, 
the case for patients with an Hb <10.0 g/dL. We also found 
that patients with preoperative anemia received more units of 
blood transfusions before and at 24 and 72 hours after TAVI 
mostly in the absence of overt bleeding, whereas administra-
tion of blood transfusion was associated with 1-year mortality 
in a dose-dependent manner.
Prevalence and Factors Associated With Anemia
The prevalence of anemia of 57% reported herein is higher 
than that demonstrated in patients with acute coronary syn-
drome or congestive heart failure and in patients undergo-
ing percutaneous coronary intervention or cardiac surgery 
(≤41.9%).5,7–9,13 This is most likely explained by differences 
in patient characteristics. Patients who are referred for TAVI 
are older and, therefore, more often have associated cardiac 
and noncardiac chronic disease or comorbid conditions, 
which both may explain a higher prevalence of anemia in 
these patients.4,28,29 In accordance with 4 previous studies that 
reported the cause or determinants of anemia in patients with 
heart disease, we found kidney impairment and peripheral 
vascular disease to be related to preoperative anemia.7,12,15,30 
These and almost all other factors associated with anemia in 
the present analysis are common in patients with anemia and 
frequently seen in patients who currently undergo TAVI. For 
instance, we found a prevalence of chronic kidney disease in 
60% of the patients, heart failure in 57%, peripheral vascular 
disease in 28%, and malignancy in 12%. A prevalence of 57% 
of anemia is, therefore, not surprising. The information of the 
presence of anemia and its associated conditions may help to 
improve patient selection and planning of TAVI. It is conceiv-
able that the optimization of some of the baseline conditions 
that are associated with anemia may positively affect outcome 
(eg, optimization of heart failure, prehydration).
Prognostic Effects of Preoperative Anemia and 
Blood Transfusions
The main objective of the present study was to assess whether 
preoperative anemia was independently associated with (short- 
and long-term) mortality rather than being a marker of disease. 
For that purpose, multivariable analyses were performed. With 
respect to 30-day mortality, preoperative anemia was not inde-
pendently associated with 30-day mortality (P=0.073). Several 
postoperative complications (in particular, valve dysfunction 
[ie, aortic regurgitation] and renal failure) and a few baseline 
variables (such as male sex and preoperative atrial fibrilla-
tion) showed a stronger relationship with mortality. We could 
not study the association between the severity of preoperative 
anemia (ie, Hb levels) and 30-day mortality because of a low 
absolute number of deaths in some of the Hb categories. Yet, 
what we perceive as an even more important clinical obser-
vation is that patients with preoperative anemia receive more 
units of blood transfusion during the perioperative period and 
that every unit of transfusion is associated with a 25% increase 
in risk of 30-day mortality, which was also found in the assess-
ment of long-term mortality albeit that the association was 
Table 6. Multivariable Cox Regression Analysis for 
Associations With Cumulative 1-Year Mortality After 
Transcatheter Aortic Valve Implantation
Hazard Ratio
(95% CI)Determinant P Value
Preoperative anemia 1.42 (1.12–1.81) 0.004
Preoperative hemoglobin (per g/dL increase) 0.87 (0.81–0.94) <0.001
Preoperative hemoglobin category, g/dL*
  ≥15 vs 14 to 15 (n=66) 1.26 (0.60–2.62) 0.54
  14 to 15 (n=129) Reference
  13 to 14 vs 14 to 15 (n=304) 1.66 (0.97–2.84) 0.063
  12 to 13 vs 14 to 15 (n=369) 1.44 (0.84–2.49) 0.19
  11 to 12 vs 14 to 15 (n=376) 1.87 (1.10–3.19) 0.021
  10 to 11 vs 14 to 15 (n=272) 2.49 (1.46–4.23) 0.001
  <10 vs 14 to 15 (n=180) 2.78 (1.60–4.82) <0.001
Acute kidney injury, stages I–III 1.97 (1.53–2.54) <0.001
Preoperative atrial fibrillation 1.77 (1.41–2.23) <0.001
Postoperative aortic regurgitation grade ≥III 1.66 (1.09–2.53) 0.019
Male sex 1.53 (1.22–1.93) <0.001
History of malignancy 1.51 (1.12–2.04) 0.007
Peripheral vascular disease 1.34 (1.05–1.70) 0.020
Blood transfusion ≤24 h (per 1 U increase) 1.09 (1.03–1.14) 0.001
Preoperative left ventricular ejection fraction 
(per 10% increase)
0.90 (0.83–0.98) 0.011
Body mass index (per 1 kg/m2 increase) 0.97 (0.95–0.99) 0.036
Maximum leukocyte count ≤72 h (per 1×109 
cells/L increase)
1.05 (1.02–1.07) <0.001
Logistic EuroSCORE (per 1% increase) 1.01 (1.0–1.02) 0.009
CI indicates confidence interval; and EuroSCORE, European System for 
Cardiac Operative Risk Evaluation.
*To establish the dose-dependent effect of decreased vs normal preoperative 
hemoglobin values (=14 to 15 g/dL) on cumulative 1-year mortality, hazard ratio 
values of decreased hemoglobin levels are shown in steps of 1 g/dL, and each 
was compared with patients with hemoglobin values between 14 and 15 g/dL.
Table 5. Multivariable Logistic Regression Analysis for 
Associations With 30-Day Mortality After Transcatheter Aortic 
Valve Implantation
Odds Ratio
(95% CI)Determinant P Value
Preoperative anemia 1.72 (0.96–3.12) 0.073
Preoperative hemoglobin (per 1 g/dL increase) 0.90 (0.77–0.77) 0.20
Postoperative aortic regurgitation grade ≥III 5.07 (2.02–12.65) 0.001
Acute kidney injury, stages I–III 3.21 (1.83–5.64) <0.001
Male sex 2.25 (1.25–4.06) 0.007
Postoperative mitral regurgitation grade ≥III 2.13 (1.06–4.27) 0.034
Preoperative atrial fibrillation 2.03 (1.16–3.53) 0.013
Blood transfusion ≤24 h (per 1 U increase) 1.25 (1.08–3.67) 0.004
Maximum leukocyte count ≤72 h (per 1×109 
cells/L increase)
1.10 (1.05–1.16) <0.001
Logistic EuroSCORE (per 1% increase) 1.03 (1.02–1.04) <0.001
Preoperative peak gradient (per 10 mm Hg 
increase)
0.84 (0.74–0.96) 0.008
CI indicates confidence interval; and EuroSCORE, European System for 
Cardiac Operative Risk Evaluation.
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less pronounced (increase in risk of 9% per transfusion). In 
this study, the possibility of heterogeneity in timing of the 
collection of data in each institution precluded an accurate 
estimation of the total blood loss calculated by the Landefeld 
equation (which assumes that the net Hb decline corresponds 
to the addition of the number of blood transfusion to the base-
line minus measured postoperative nadir Hb).31 Yet, in accor-
dance with our previous findings,32 the current results show 
that patients with anemia had a smaller postoperative Hb drop 
but received significantly more frequent and also more units 
of blood transfusions compared with patients without anemia 
(Figure 3). Also, the indication of blood transfusion was not 
related to an overt source of bleeding in ≈60% of patients with 
anemia. Therefore, in the context of the significant and inverse 
relationship between blood transfusion and mortality, the big-
gest gain is to be expected from a more restrictive use of blood 
transfusions in addition to the need of uniform criteria for the 
use of blood products. The optimization of baseline factors 
related to preoperative anemia, in addition to measures aimed 
at correcting or treating anemia and its cause, may conceptu-
ally also reduce the use of perioperative blood transfusions.
In essence, the same observations were made when study-
ing the associations with mortality during follow-up. The 
difference, however, was the significant inverse relationship 
between the severity of preoperative anemia (ie, Hb level) 
and late death, in particular when the Hb level was <10 g/dL. 
Preoperative anemia defined by the World Health Organization 
criteria had a weak association, whereas—in descending order 
of hazard—acute kidney injury, postoperative aortic regurgita-
tion, and a few baseline patient-related variables such as pre-
operative atrial fibrillation, male sex, and peripheral vascular 
disease were more strongly associated with late death.
Limitations
Preoperative anemia was associated with short- and long-term 
mortality by multivariable analysis. Yet, it should be acknowl-
edged that a multivariable analysis does not disclose the 
nature (eg, causal) of the observed relationship. Also, despite 
the fact that the factors associated with anemia were searched 
by reviewing all medical charts, it is unknown how many fac-
tors in how many patients remained undetected. Based on the 
results of the present study, it is plausible that a more restric-
tive use of blood transfusion may be beneficial. Yet, the study 
does not allow to make proposals of a more restrictive transfu-
sion protocol.
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